- call +1-201-465-4211
- email sales@mrinsights.biz
The standard definition of high blood pressure is determined by the Joint National Committee (JNC) on Detection, Evaluation, and Diagnosis of High Blood Pressure. A person is considered to have high blood pressure after three to six elevated blood pressure measurements over several months. These definitions apply to adults who are healthy and not using medication for high blood pressure. If the two pressures fall in different categories, the higher one is used to determine the severity of hypertension.
Scope of the Report:
This report focuses on the Hypertension Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
With an increase in the population of older people, the market for hypertension drugs has a positive outlook over the forecast period. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Since the risk of developing pulmonary hypertension increases with age, a growing older population will aid in the growth prospects of the hypertension drugs market in the coming years.
In 2015, the Americas was the largest market for hypertension drugs as it accounted for more than 44% of the market share. The US is the major revenue contributor in the region. The market share is declining due to the patent expiries of drugs such as Micardis, Avapro, and Diovan. However, comorbid conditions among the older population like congenital heart disease and increasing focus on combination therapies will prevent the decline in the market. Moreover, the launch of new disease-modifying therapies is expected to bolster the growth prospects of the market during the forecast period.
The worldwide market for Hypertension Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novartis
Daiichi Sankyo
Actelion Pharmaceuticals
Boehringer Ingelheim
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
There are 15 Chapters to deeply display the global Hypertension Drugs market.
Chapter 1, to describe Hypertension Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hypertension Drugs, with sales, revenue, and price of Hypertension Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hypertension Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hypertension Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hypertension Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Hypertension Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Calcium Channel Blockers
1.2.2 Diuretics
1.2.3 Beta Blockers Vasodilators
1.2.4 Angiotensin Converting Enzyme Inhibitors
1.2.5 Alpha Blockers
1.2.6 Angiotensin Receptor Blockers
1.2.7 Renin Inhibitors
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Business Overview
2.1.2 Hypertension Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novartis Hypertension Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Daiichi Sankyo
2.2.1 Business Overview
2.2.2 Hypertension Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Daiichi Sankyo Hypertension Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Actelion Pharmaceuticals
2.3.1 Business Overview
2.3.2 Hypertension Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Actelion Pharmaceuticals Hypertension Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Boehringer Ingelheim
2.4.1 Business Overview
2.4.2 Hypertension Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Boehringer Ingelheim Hypertension Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Hypertension Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Hypertension Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hypertension Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Hypertension Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Hypertension Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Hypertension Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Hypertension Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Hypertension Drugs Market Analysis by Regions
4.1 Global Hypertension Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Hypertension Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Hypertension Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Hypertension Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Hypertension Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Hypertension Drugs Sales and Growth Rate (2013-2018)
4.5 South America Hypertension Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Hypertension Drugs Sales and Growth Rate (2013-2018)
5 North America Hypertension Drugs by Countries
5.1 North America Hypertension Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Hypertension Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Hypertension Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Hypertension Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Hypertension Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Hypertension Drugs Sales and Growth Rate (2013-2018)
6 Europe Hypertension Drugs by Countries
6.1 Europe Hypertension Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Hypertension Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Hypertension Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Hypertension Drugs Sales and Growth Rate (2013-2018)
6.3 UK Hypertension Drugs Sales and Growth Rate (2013-2018)
6.4 France Hypertension Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Hypertension Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Hypertension Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Hypertension Drugs by Countries
7.1 Asia-Pacific Hypertension Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Hypertension Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Hypertension Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Hypertension Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Hypertension Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Hypertension Drugs Sales and Growth Rate (2013-2018)
7.5 India Hypertension Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Hypertension Drugs Sales and Growth Rate (2013-2018)
8 South America Hypertension Drugs by Countries
8.1 South America Hypertension Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Hypertension Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Hypertension Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Hypertension Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Hypertension Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Hypertension Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Hypertension Drugs by Countries
9.1 Middle East and Africa Hypertension Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Hypertension Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Hypertension Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Hypertension Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Hypertension Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Hypertension Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Hypertension Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Hypertension Drugs Sales and Growth Rate (2013-2018)
10 Global Hypertension Drugs Market Segment by Type
10.1 Global Hypertension Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Hypertension Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Hypertension Drugs Revenue and Market Share by Type (2013-2018)
10.2 Calcium Channel Blockers Sales Growth and Price
10.2.1 Global Calcium Channel Blockers Sales Growth (2013-2018)
10.2.2 Global Calcium Channel Blockers Price (2013-2018)
10.3 Diuretics Sales Growth and Price
10.3.1 Global Diuretics Sales Growth (2013-2018)
10.3.2 Global Diuretics Price (2013-2018)
10.4 Beta Blockers Vasodilators Sales Growth and Price
10.4.1 Global Beta Blockers Vasodilators Sales Growth (2013-2018)
10.4.2 Global Beta Blockers Vasodilators Price (2013-2018)
10.5 Angiotensin Converting Enzyme Inhibitors Sales Growth and Price
10.5.1 Global Angiotensin Converting Enzyme Inhibitors Sales Growth (2013-2018)
10.5.2 Global Angiotensin Converting Enzyme Inhibitors Price (2013-2018)
10.6 Alpha Blockers Sales Growth and Price
10.6.1 Global Alpha Blockers Sales Growth (2013-2018)
10.6.2 Global Alpha Blockers Price (2013-2018)
10.7 Angiotensin Receptor Blockers Sales Growth and Price
10.7.1 Global Angiotensin Receptor Blockers Sales Growth (2013-2018)
10.7.2 Global Angiotensin Receptor Blockers Price (2013-2018)
10.8 Renin Inhibitors Sales Growth and Price
10.8.1 Global Renin Inhibitors Sales Growth (2013-2018)
10.8.2 Global Renin Inhibitors Price (2013-2018)
11 Global Hypertension Drugs Market Segment by Application
11.1 Global Hypertension Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Hypertension Drugs Market Forecast (2018-2023)
12.1 Global Hypertension Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Hypertension Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Hypertension Drugs Market Forecast (2018-2023)
12.2.2 Europe Hypertension Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Hypertension Drugs Market Forecast (2018-2023)
12.2.4 South America Hypertension Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Hypertension Drugs Market Forecast (2018-2023)
12.3 Hypertension Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Hypertension Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Hypertension Drugs Market Share Forecast by Type (2018-2023)
12.4 Hypertension Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Hypertension Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Hypertension Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Hypertension Drugs Picture
Table Product Specifications of Hypertension Drugs
Figure Global Sales Market Share of Hypertension Drugs by Types in 2017
Ta
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
